Goupil A, Baglin A, Clavel B, Verger C, Fritel D
Nouv Presse Med. 1980 Nov 1;9(41):3069-70.
Terminal chronic renal failure was discovered in a patient who had received CCNU 1 940 mg/m2 during the previous two years. The renal function was normal before treatment, and there was no evidence of other causes of renal failure. The clinical picture was identical with that observed in patients receiving such treatment and recently published. This case emphasizes the need for limiting the dose of nitrosyl-urea compounds to 1 200 mg/m2 and for monitoring the renal function very closely during and towards the end of the treatment.
在一名此前两年内接受过1940mg/m²洛莫司汀治疗的患者身上发现了终末期慢性肾衰竭。治疗前肾功能正常，且无其他肾衰竭病因的证据。临床表现与接受此类治疗的患者所观察到的以及最近发表的情况相同。该病例强调了将亚硝基脲类化合物剂量限制在1200mg/m²的必要性，以及在治疗期间和接近治疗结束时密切监测肾功能的必要性。
